SEC Form 4 · accession 0001429931-26-000002
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tibor Keler
Officer — EXECUTIVE VP & CSO
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000744218
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1,F2 | $34.09 | Jun 25, 2026 | A | 115,000 | A | Jun 25, 2027 | Jun 25, 2036 | Common Stock | 115,000 | 115,000 | D |
Explanation of responses
- F1Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
- F225% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.